Drug recall · July 17, 2013
Nicardipine Hydrochloride Injection 25 mg/10 mL recall
Why: Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Nicardipine Hydrochloride Injection 25 mg/10 mL (2.5 mg/mL), 10 mL single-use vials, Rx Only, Mfd. by Exela Pharma Sciences, LLC, Lenoir, NC, Dist. by: West-ward Pharmaceutical Corp., Eatontown, NJ --- NDC 0143-9689-10
- Lots / codes
Lot PLNJ1201 APRIL 2014 Lot PLNJ1202 MAY 2014
- Quantity
- Lot PLNJ1201 -16,880 vials ; Lot PLNJ1202 - 16,960 vials
- Company
- West-ward Pharmaceutical Corp., Eatontown, NJ
- Distribution
- Nationwide
- Initiated
- May 13, 2013 · Voluntary: Firm initiated
- Classified
- July 11, 2013
- Reported
- July 17, 2013
- Ended
- March 17, 2015
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nicardipine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.